Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 200 of 2995 results for all

  1. Intravenous fluid therapy in children and young people in hospital (NG29)

    This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.

  2. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

  3. Major trauma: service delivery (NG40)

    This guideline covers the organisation and provision of major trauma services in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by providing a systematic approach to the delivery of major trauma care. It does not cover services for people with burns.

  4. Drug misuse in over 16s: opioid detoxification (CG52)

    This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  5. Home care: delivering personal care and practical support to older people living in their own homes (NG21)

    This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.

  6. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

  7. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

  8. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  9. Improving outcomes for people with sarcoma (CSG9)

    This guideline covers how healthcare services for people with sarcoma should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  10. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  11. Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)

    NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the appraisal.

    Sections for TA1078

  12. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    (including experience to date from the risk-sharing scheme) and includes all currently available treatments. Any explanatory notes(if...

  13. Intrapartum care (QS105)

    This quality standard covers the care of women and their babies during labour and immediately after the birth. It covers women who go into labour at term, and includes women at low risk of complications during labour and those who go on to develop complications. It describes high-quality care in priority areas for improvement.

  14. Learning disabilities and behaviour that challenges: service design and delivery (NG93)

    This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

  15. Nutrition support in adults (QS24)

    This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.

  16. Ovarian cancer: recognition and initial management (CG122)

    This guideline covers detecting, diagnosing and treating women (aged 18 and over) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.

  17. Thyroid disease: assessment and management (NG145)

    This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.

  18. Improving outcomes in head and neck cancers (CSG6)

    This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  19. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  20. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  21. Improving outcomes for people with skin tumours including melanoma (CSG8)

    This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.

  22. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

  23. Psychosis and schizophrenia in adults: prevention and management (CG178)

    This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.

  24. Community engagement: improving health and wellbeing and reducing health inequalities (NG44)

    This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

  25. Vasculitis

    All NICE products on vasculitis. Includes any guidance.

  26. Acne

    All NICE products on acne. Includes any guidance.

  27. Mesothelioma

    All NICE products on mesothelioma. Includes any guidance.

  28. Staffing

    All NICE products on staffing. Includes any guidance.

  29. Transport

    All NICE products on transport. Includes any guidance.

  30. Lymphoedema

    All NICE products on lymphoedema. Includes any guidance.

  31. ME/CFS

    All NICE products on ME/CFS. Includes any guidance.

  32. Systemic lupus erythematosus

    All NICE products on systemic lupus erythematosus. Includes any guidance.

  33. Health inequalities

    All NICE products on health inequalities. Includes any guidance.

  34. Sunlight exposure

    All NICE products on sunlight exposure. Includes any guidance.

  35. Peritoneal cancer

    All NICE products on peritoneal cancer. Includes any guidance.

  36. Maxillofacial conditions

    All NICE products on maxillofacial conditions. Includes any guidance.

  37. Parathyroid disorders

    All NICE products on parathyroid disorders. Includes any guidance.

  38. Thyroid cancer

    All NICE products on thyroid cancer. Includes any guidance.

  39. Thyroid disorders

    All NICE products on thyroid disorders. Includes any guidance.

  40. Adrenal dysfunction

    All NICE products on adrenal dysfunction. Includes any guidance.

  41. Vaginal conditions

    All NICE products on vaginal conditions. Includes any guidance.

  42. Uterine prolapse

    All NICE products on uterine prolapse. Includes any guidance.

  43. Endometrial cancers

    All NICE products on endometrial cancers. Includes any guidance.

  44. Cervical cancer

    All NICE products on cervical cancer. Includes any guidance.

  45. Liver cancers

    All NICE products on liver cancers. Includes any guidance.

  46. Diverticular disease

    All NICE products on diverticular disease. Includes any guidance.

  47. Addiction

    All NICE products on addiction. Includes any guidance and advice.

  48. Spasticity

    All NICE products on spasticity. Includes any guidance and advice.

  49. Hernia

    All NICE products on hernia. Includes any guidance and advice.

  50. Gastroparesis

    All NICE products on gastroparesis. Includes any guidance and advice.